by Thomas E. Levy, MD, JD
As of the writing of this
article, multiple news reports have recently addressed the
monkeypox virus infections in humans.
In the current setting of
the entire planet dealing with
the COVID 'pandemic' over the last two
and a half years, fear is readily stoked that another 'pandemic' with
a virus that comes from the same family of viruses as smallpox could
be poised to inflict widespread suffering and death.
This article will present
the significant scientific data and literature surrounding monkeypox
infection in humans, which clearly demonstrates that the monkeypox
virus presents NO threat of a 'pandemic' or even a large epidemic.
Although many have never heard of it until recently, monkeypox
infection is not the result of the emergence of a new virus.
it was first identified in captive cynomolgus monkeys in Denmark in
The first documented
human infection was reported in 1970 in a 9-month-old in the Congo.
After clinically recovering from the infection and its associated
rash over a month-long period, this baby then contracted the measles
and died six days later. 2
While not found
exclusively in remote populations in Central and West Africa,
limited monkeypox outbreaks appear to have occurred most commonly in
such areas of the world, where advanced malnutrition can potentially
make some otherwise benign infections life-threatening. 3
This initial case also
serves to highlight the fact that underlying chronic malnutrition
with moderate to severely depleted vitamin and mineral stores in
those living in such remote areas of Africa literally sets the stage
for contracting any infectious disease.
measles upon the resolution of the monkeypox virus is the logical
result of such an advanced depletion of nutrients in the body.
The typical mild to
moderate clinical presentation of the measles can easily evolve into
a fatal infection when a chronic state of nutrient depletion is
still further depleted by a month-long bout with the monkeypox
Monkeypox cases have only occurred as very limited outbreaks, never
as an epidemic or a 'pandemic'.
Such an outbreak is a
cluster of cases in a given area from a pathogen with a limited
contagion risk. An epidemic/'pandemic' requires a pathogen that is
very easily spread.
This is not the case with
the monkeypox virus.
The United States has already had an outbreak
of monkeypox infection in 2003, involving 47 human cases felt to be
secondary to the importation of infected wild rodents from Ghana.
No secondary larger
outbreak or epidemic resulted, however.
human-to-human transmission was documented. 4
human-to-human transmission is certainly possible, it is the
exposure to and/or the consumption of infected animals, as well as
their consumption of each other, that both spreads this virus and
serves as a reservoir for it.
This is an additional
reason for its primary presence in Africa, in addition to the
overall poor nutrition on much of this continent. 5,6
Monkeypox is characterized as a zoonotic infection, meaning it can
transmit from animal to human, or vice-versa. 7
infections are very common, as over half of the healthy persons in
an area of Ghana, which actually had no reported clinical human
cases of monkeypox at the time of this study, had positive
immunoglobulin G (IgG) antibodies against the monkeypox virus genus.
A similarly large
percentage of the healthy residents in a region of the Congo had
circulating antibodies as well. 9
Another study in Cameroon
found these antibodies in slightly over a third of the subjects
This indicates that
monkeypox is not typically severe
in its clinical course, much less fatal, in any human population...
And this would especially
be the case in the United States or in a comparable country with a
relatively high-quality level of nutrition as well as a relatively
widespread intake of vitamin and mineral supplementation.
Ebola, another virus that has been largely limited to African
countries, resulted in a substantial outbreak in West Africa from
2014 to 2016, but it never approached 'pandemic' or even significant
Nevertheless, in the
nutrition-depleted populations in which it emerged, death resulted
in those individuals demonstrating clinical infection between 25%
and 90% of the time, enough to generate a great deal of fear that it
could spread and kill easily throughout the world. 11
And even though Ebola
killed many who became infected, a substantial number of those
individuals exposed developed natural immunity (IgG antibody)
response without ever becoming clinically ill.
Depending on the location
of the African community and the conditions of the testing protocol
up to 50% of exposed individuals, including those living
with clinically infected individuals, showed the development of
natural antibodies to Ebola without ever becoming ill. 12-18
And in spite of the
initial fear that was generated, no 'pandemic', epidemic, or even
minor outbreak of Ebola ever occurred in the United States, even
though international airline travel reliably introduced infected
individuals into the country. 19,20
Most of the fear currently seen with the potential spread of the
monkeypox virus is due to the fact that both monkeypox and smallpox
comes from the same genus of DNA viruses. 21
Smallpox has been
estimated to have killed between 300 and 500 million people in the
20th century... 22
anything that is remotely related to smallpox can be expected to
generate a great deal of concern.
While the smallpox vaccine is credited for the effective eradication
of smallpox, it is also believed by some that waning vaccine
immunity is currently leaving over 70% of the world's population
unprotected against smallpox, as this vaccine has not been routinely
administered since 1980. 23
Some estimates indicate
that the smallpox vaccination has offered roughly an 85% protection
against monkeypox infection. 24
And since the vaccine
immunity against smallpox is felt to be waning, the associated
cross-immunity against related viruses like monkeypox is felt to be
fading as well. 25
However, monkeypox is simply not smallpox.
The evidence presented
above indicates that many asymptomatic infections occur with monkeypox, and that it is far less contagious than smallpox, with
human-to-human transmission being decidedly uncommon.
Concurrent epidemics or
outbreaks of smallpox and monkeypox have not been reported, and
smallpox is not a zoonotic infection like monkeypox, but infects
humans only. 26
Finally, in the more well-fed and healthy populations in the world,
monkeypox is simply not a killer virus once contracted. The typical
clinical course of monkeypox in such populations much more resembles
chickenpox than smallpox.
Even if the presumed
waning protection of the old smallpox vaccinations results in some
increase in human monkeypox cases, it will not turn monkeypox into
the highly contagious and deadly killer that is smallpox.
Prevented, Readily Resolved
While some viruses are much more contagious and much more capable of
causing severe illness and even death than others, they all share
As devastating as Ebola
has been to many of the individuals in Africa who have contracted
it, bio-oxidative treatment readily resolves it as well as any other
virus that is treated before too much advanced organ damage has
already taken place.
At the height of
Ebola scare in 2014, Drs. Robert Rowen and Howard Robins were so
convinced of their ability to cure Ebola infections that they put
themselves directly in harm's way by traveling to Sierra Leone, a
West African epicenter of Ebola infection at that time.
Of note, many physicians
and other healthcare providers in this area of Africa were dying
from the infection at that time.
The primary therapy they used to treat the Ebola patients was ozone.
And even though great local resistance was met in gaining access to
patients, four individuals were successfully treated with ozone
The cornerstone ozone
application was direct intravenous ozone gas injection.
Supplemental oral vitamin
C therapy was administered as well to address its infection-induced
deficiency, to bolster immune function, and to minimize the impact
of any possible pro-oxidant Herxheimer-like rapid virus kill-off
All four patients
improved immediately after the first treatment and complete
resolution of their infections was seen between two to five days.
Furthermore, no progression of any Ebola-related symptoms was seen
after the first ozone treatments were administered. 27
Other acute viral syndromes that have initially had much of the
world on edge in recent years have also been proven to be readily
curable, although not with any known prescription drugs.
virus received a lot of attention, and some outbreaks with this
virus were sizeable, although never really reaching epidemic
This viral infection
typically left those infected with debilitating symptoms, often
resulting in severe pain in many of the joints in the body.
The most immunocompetent
individuals would often resolve their most severe symptoms in about
a week, but in some the joint pain would become chronic and last as
long as five years.
intravenous infusions with two bio-oxidative agents,
vitamin C and
...in 56 patients were highly effective in both
completely resolving this viral infection, as well as in immediately
alleviating much of the chronic pain that remained long after the
acute phase of the infection. 28
Treatment with just
high-dose vitamin C intravenously (as much as 100 grams daily) in
the acute stage of viral infection with Chikungunya, influenza, Zika,
and dengue has also been reported to be similarly curative.
In a nutshell, unless the patient has advanced organ damage and is
very near death, intravenous vitamin C, in sufficient doses, can
always be expected to save the patient from succumbing to an
advanced infection, especially viral.
As the primary
electron-donating nutrient in the body, enough vitamin C must be
administered to both neutralize the new, ongoing infection-derived
pro-oxidants (toxins) while restoring (reducing) the physiological
function of those biomolecules that have already been oxidized.
A sizeable number of
integrative medicine practitioners who appreciate the therapeutic
value of IV vitamin C remain needlessly wary of 50- to 100-gram
infusions of vitamin C.
This unnecessary caution
too often results in a total daily dose of vitamin C of 25 grams or
less that proves insufficient to save the patient with severe and
widespread oxidative damage secondary to an advanced infection.
Nevertheless, even such lower doses can oftentimes suffice, just not
as reliably so.
The experience at the Riordan Clinic alone in Wichita, Kansas
clearly establishes the safety (and efficacy) of even the highest
dosing regimens of vitamin C on a routine basis.
Over the past 32 years,
over 150,000 intravenous infusions of vitamin C have been
administered at Riordan campuses.
Doses have varied from
7.5 to 250 grams daily, with 50 grams being the most common dose
administered. NO significant adverse side effects have occurred, and
NO kidney stones have resulted.
For more information on
the vitamin C-related research and results of the Riordan Clinic,
The primary bio-oxidative therapies (vitamin C, hydrogen peroxide,
ozone, ultraviolet blood irradiation, and hyperbaric oxygen) have
all been shown to eradicate any viral infections for which they have
been properly administered.
As noted above,
intravenous ozone can promptly resolve even an advanced viral
infection whenever access to it is available.
intravenous hydrogen peroxide is comparably effective, and as long
as the healthcare practitioner is willing to use it, its expense is
nominal and it is available literally everywhere.
Vitamin C, ultraviolet
blood irradiation, and hyperbaric oxygen therapy are incredibly
effective as well, but less available and anywhere from slightly to
substantially more expensive to apply than the hydrogen peroxide
and/or the ozone therapies.
These therapies, along
with other supportive antipathogenic measures, are discussed in
greater detail elsewhere. 33
Another great option for dealing with any virus once contracted is a
combination vitamin C-cortisol approach, especially when the
intravenous administration of bio-oxidative agents is not readily
available, if at all.
A sizeable oral dose of
vitamin C (3 to 5 grams, liposome-encapsulated or as sodium
ascorbate powder) along with 20 mg of cortisol (hydrocortisone) is
dramatically effective in its clinical impact, often resulting in a
prompt cessation of infection evolution followed shortly thereafter
by complete resolution.
As a very general
guideline, the vitamin C/cortisol should be taken three times daily
until baseline health is restored. Complete clinical resolution is
typically seen in 12 to 36 hours.
A more prolonged
treatment plan is only required when the pathogen has had a longer
time to replicate and clinical illness is more pronounced when
therapy is initiated. 34,35
Monkeypox virus should never be confused with smallpox, even though
the viruses have some common family roots.
Smallpox is a human
infection, and monkeypox is primarily limited to infections in
susceptible animal populations...
When monkeypox does
infect a human, its clinical course is little more than that of a
typical case of chickenpox, as long as the infected individual is
not grossly malnourished.
And even in populations
with significant nutrient depletion, monkeypox is very often a
completely asymptomatic infection, as high levels of protective
antibodies to monkeypox have been documented in significant
percentages of these populations.
Also, unlike smallpox,
monkeypox has both a very low level of contagion and only
results in a fatal outcome, even in the most susceptible of
A good level of nutrition, along with judicious supplementation with
vitamins and minerals, will almost completely prevent the
transmission of monkeypox, from either an infected animal or human.
And when it is
contracted, the application of any of a number of bio-oxidative and
other therapies will give a rapid resolution to this infection.
This ease of prevention
and susceptibility to rapid cure should be kept in mind before
deciding to proceed directly with any monkeypox vaccinations that
end up being offered to the public...
1. Magnus P,
Andersen E, Petersen K, Birch-Andersen A (1959) A pox-like
disease in cynomolgus monkeys. Acta Pathologica, Microbiologica,
et Immunologica Scandinavica 46:156-176.
2. Ladnyj I,
Ziegler P, Kima E (1972) A human infection caused by monkeypox
virus in Basankusu Territory, Democratic Republic of the Congo.
Bulletin of the World Health Organization 46:593-597. PMID:
3. Beer E, Rao
V (2019) A systematic review of the epidemiology of human
monkeypox outbreaks and implications for outbreak strategy. PLoS
Neglected Tropical Diseases 13:e0007791. PMID:
4. Reynolds M,
Davidson W, Curns A et al. (2007) Spectrum of infection and risk
factors for human monkeypox, United States, 2003. Emerging
Infectious Diseases 13:1332-1339. PMID:
5. Ye F, Song
J, Zhao L et al. (2019) Molecular evidence of human monkeypox
virus infection, Sierra Leone. Emerging Infectious Diseases
6. Patrono L,
Pleh K, Samuni L et al. (2020) Monkeypox virus emergence in wild
chimpanzees reveals distinct clinical outcomes and viral
diversity. Nature Microbiology 5:955-965. PMID:
7. Eltvedt A,
Christiansen M, Poulsen A (2020) A case report of monkeypox in a
4-year-old boy from the DR Congo: challenges of diagnosis and
management. Case Reports in Pediatrics 2020:8572596. PMID:
8. Reynolds M,
Carroll D, Olson V et al. (2010) A silent enzootic of an
orthopoxvirus in Ghana, West Africa: evidence for multi-species
involvement in the absence of widespread human disease. The
American Journal of Tropical Medicine and Hygiene 82:746-754.
9. Lederman E,
Reynolds M, Karem K et al. (2007) Prevalence of antibodies
against orthopoxviruses among residents of Likouala region,
Republic of Congo: evidence for monkeypox virus exposure. The
American Journal of Tropical Medicine and Hygiene 77:1150-1156.
S, Monroe B, Moundjoa C et al. (2020) Asymptomatic orthopoxvirus
circulation in humans in the wake of a monkeypox outbreak among
chimpanzees in Cameroon. The American Journal of Tropical
Medicine and Hygiene 102:206-212. PMID:
L, Kankya C, Krontveit R et al. (2016) How severe and prevalent
are Ebola and Marburg viruses? A systematic review and
meta-analysis of the case fatality rates and seroprevalence. BMC
Infectious Diseases 16:708. PMID:
12. Baxter A
(2000) Symptomless infection with Ebola virus. The Lancet
13. Mulangu S,
Borchert M, Paweska J et al. (2016) High prevalence of IgG
antibodies to Ebola virus in the Efe' pygmy population in the
Watsa region, Democratic Republic of the Congo. BMC Infectious
Diseases 16:263. PMID:
14. Mafopa N,
Russo G, Wadoum R et al. (2017) Seroprevalence of Ebola virus
infection in Bombali District, Sierra Leone. Journal of Public
Health in Africa 8:732. PMID:
15. Mbala P,
Baguelin M, Ngay I et al. (2017) Evaluating the frequency of
asymptomatic Ebola virus infection. Philosophical Transactions
of the Royal Society of London. Series B, Biological Sciences
16. Timothy J,
Hall Y, Akoi-Bore J et al. (2019) Early transmission and case
fatality of Ebola virus at the index site of the 2013-2016 West
African Ebola outbreak: a cross-sectional seroprevalence survey.
The Lancet. Infectious Diseases 19:429-438. PMID:
17. Bratcher A,
Hoff N, Doshi R et al. (2021) Zoonotic risk factors associated
with seroprevalence of Ebola virus GP antibodies in the absence
of diagnosed Ebola virus disease in the Democratic Republic of
Congo. PLoS Neglected Tropical Diseases 15:e0009566. PMID:
18. Manno D,
Ayieko P, Ishola D et al. (2022) Ebola virus glycoprotein IgG
seroprevalence in community previously affected by Ebola, Sierra
Leone. Emerging Infectious Diseases 28:734-738. PMID:
19. Fairley J,
Kozarsky P, Kraft C et al. (2016) Ebola or not? Evaluating the
ill traveler from Ebola-affected countries in West Africa. Open
Forum Infectious Diseases 3:ofw005. PMID:
20. Rauch S,
Jasny E, Schmidt K, Petsch B (2018) New vaccine technologies to
combat outbreak situations. Frontiers in Immunology 9:1963. PMID:
21. Babkin I,
Babkina I, Tikunova N (2022) An update of orthopoxvirus
molecular evolution. Viruses 14:388. PMID:
B, Vinner L, Margaryan A et al. (2020) Diverse variola virus
(smallpox) strains were widespread in northern Europe in the
Viking Age. Science 369:eaaw8977. PMID:
23. Rao A,
Schulte J, Chen T et al. (2022) Monkeypox in a traveler
returning from Nigeria-Dallas, Texas, July 2021. MMWR. Morbidity
and Mortality Weekly Report 71:509-516. PMID:
24. Fine P,
Jezek Z, Grab B, Dixon H (1988) The transmission potential of
monkeypox virus in human populations. International Journal of
Epidemiology 17:643-650. PMID:
25. Simpson K,
Heymann D, Brown C et al. (2020) Human monkeypox-after 40 years,
an unintended consequence of smallpox eradication. Vaccine
26. Grant R,
Nguyen L, Breban R (2020) Modelling human-to-human transmission
of monkeypox. Bulletin of the World Health Organization
27. Rowen R,
Robins H, Carew K et al. (2016) Rapid resolution of hemorrhagic
fever (Ebola) in Sierra Leone with ozone therapy. African
Journal of Infectious Diseases 10:49-54.
V, Gonzalez-Terron G, Levy T (2015) Intravenous ascorbic acid
and hydrogen peroxide in the management of patients with
Chikungunya. Boletin de la Asociacion Medica de Puerto Rico
29. Gonzalez M,
Miranda-Massari J, Berdiel M et al. (2014) High dose intravenous
vitamin C and Chikungunya fever: a case report. Journal of
Orthomolecular Medicine volume 29.
30. Gonzalez M,
Berdiel M, Miranda-Massari J et al. (2016) High dose intravenous
vitamin C treatment for Zika fever. Journal of Orthomolecular
Medicine volume 31.
31. Gonzalez M,
Berdiel M, Duconje J et al. (2018) High dose intravenous vitamin
C and influenza: a case report. Journal of Orthomolecular
Medicine volume 33.
J, Toro A, Loh D et al. (2021) The effects of vitamin C on the
multiple pathophysiological stages of COVID-19. Life 11:1341.
33. Levy T
(2021) Rapid Virus Recovery: No need to live in fear! Chapter
10. Henderson, NV: MedFox Publishing. Free download available
34. Levy T
35. Levy T